

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ...ANG/22-23/BSE-57

Date...30-05-2022

To

**Department of Corporate Services,
BSE Limited**
P J Towers, Dalal Street,
Mumbai- 400001

Ref: BSE Security Code-540694
Sub: **Outcome of Board Meeting**

Dear Sir

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of ANG Lifesciences India Limited at their Meeting held today i.e. Monday, May 30, 2022, at the Registered Office of the Company situated at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001 transacted the following business:

1. Considered and Approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st March 2022 along with the Auditor's Report thereon.

Copy of Financial Results along with Auditor's Report and Declaration regarding Audit Report(s) with an unmodified opinion thereupon is enclosed herewith.

2. Considered & recommended the Increase in Authorised Share Capital of the Company from Rs. 10,36,66,300 (Rupees ten crores thirty six lakhs sixty six thousand three hundred) to. Rs. 14,00,00,000 (Rupees fourteen crores), subject to the shareholders' approval.
3. Considered & recommended the Alteration in the Capital Clause of Memorandum of Association (MOA) of the company, subject to the shareholders' approval.
4. Considered & recommended the issuance of fully paid up Bonus Shares in proportion of 1:4 i.e. 1(one) fully paid up share for every 4(four) fully paid-up shares held by shareholder of the company, subject to shareholders' approval.
5. Considered & recommended to increase the Borrowing Powers of the Company pursuant to the provisions of section 180(1)(c) and other applicable provisions, if any, of the Companies Act, 2013, subject to shareholders' approval.
6. Considered & recommended the matter of increase in limit of creating charge/security over the assets/undertaking of the Company pursuant to the provisions of Section 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013, subject to shareholders' approval.

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....


7. Approved the Conduct of Postal Ballot (E-voting) for shareholders' approval for above mentioned points i.e. point no. 2, 3, 4, 5 & 6 and also approved the Postal Ballot(E-voting) notice for the aforesaid decision (as mentioned in Point No. 2, 3, 4, 5 & 6) for shareholders' approval.
8. Approved the appointment of Mr. Anjum Goyal, Proprietor of M/s. Anjum Goyal & Associates, Company Secretaries in Whole Time Practice as Scrutinizer to conduct the postal ballot (e-voting process) in true and fair manner.
9. Approved 30th May, 2022 as Cut-off date for ascertaining the list of shareholders to whom the notice of postal ballot (e-voting process) will be sent and also for reckoning voting rights.

The Board meeting was started at 5:30 P.M. and concluded at 10:45 P.M.

You are requested to please take note of the same for your record.

Thanking you,

for ANG Lifesciences India Limited,


Renu Kaur

Company Secretary

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Particulars	Date.....(₹. in lacs)
	As at 31 March 2022 Audited
A. Assets	
1. Non-current assets	
(a) Property, plant and equipment	9,261.44
(b) Capital work-in-progress	-
(c) Financial assets	
(i) Investments	2.57
(ii) Other financial assets	100.28
(d) Deferred tax asset (net)	428.52
(e) Other non-current assets	29.02
Total non-current assets	9,821.83
2. Current assets	
(a) Inventories	3,695.91
(b) Financial assets	
(i) Trade receivables	10,205.50
(ii) Cash and cash equivalents	34.60
(iii) Other bank balances	630.62
iv) Other financial assets	1,168.73
(c) Other current assets	3,545.85
Total current assets	19,281.21
Total assets	29,103.04
B. Equity and liabilities	
Equity	
(a) Equity share capital	1,036.66
(b) Other equity	7,340.25
Total equity	8,376.91
Liabilities	
1. Non-current liabilities	
(a) Financial liabilities	
(i) Borrowings	2,163.70
(ii) Trade payables	174.73
(iii) Other financial liabilities	1,547.80
(b) Deferred tax liabilities (net)	61.50
(c) Provisions	149.47
Total non-current liabilities	4,097.20
2. Current liabilities	
(a) Financial liabilities	
(i) Borrowings	5,535.81
(ii) Trade payables	
-Total outstanding dues of micro enterprises and small enterprises	6,462.37
-Total outstanding dues of creditors other than micro enterprises and small enterprises	600.53
(iii) Other financial liabilities	1,370.69
(b) Other current liabilities	750.02
(c) Provisions	18.38
(d) Current tax liabilities (net)	1,891.13
Total current liabilities	16,628.93
Total equity and liabilities	29,103.04



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated audited results for the quarter and year ended 31 March 2022

(₹ in lakhs except per share data)

Particulars	Quarter ended 31 March 2022	Quarter ended 31 December 2021	Year ended 31 March 2022
	(refer note 4) (Audited)	(Unaudited)	(Audited)
I Revenue from operations	9,537.77	4,961.02	35,430.17
II Other income	56.94	15.58	90.13
III Total revenue (I+II)	9,594.71	4,976.60	35,520.30
IV Expenses			
Cost of materials consumed	6,801.46	4,366.00	23,465.10
Changes in inventories of finished goods and work-in-progress	(86.01)	(1,124.24)	(666.89)
Employee benefits expense	575.98	557.90	2,129.01
Finance costs	391.77	200.24	890.52
Depreciation and amortisation expenses	260.61	153.41	587.52
Other expenses	972.85	629.12	3,764.99
Total expenses (IV)	8,916.66	4,782.43	30,170.25
V Profit before exceptional items and tax (III-IV)	678.05	194.17	5,350.05
VI Exceptional items	-	-	-
VII Profit before tax (V-VI)	678.05	194.17	5,350.05
Tax expense			
(1) Current tax	221.50	65.00	1,346.50
(2) Deferred tax	(68.59)	1.84	(28.10)
VIII Total tax expense (1+2)	152.90	66.84	1,318.40
IX Profit for the period (VII-VIII)	525.15	127.33	4,031.65
X Other comprehensive income:			
Items that will not be reclassified to profit or loss	14.23	8.57	27.98
Income tax relating to items that will not be reclassified to profit or loss	(4.88)	(2.16)	(7.04)
XI Total comprehensive income (IX+X)	534.50	133.74	4,052.59
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	1,036.66
XIII Other equity			7,340.25
XIV Earnings per equity share (of ₹ 10/- each)			
a) Basic	5.16	1.29	39.09
b) Diluted	5.16	1.29	39.09

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Consolidated Cash Flow Statement		(₹ in lacs)
Ref. No.	Date	Year ended 31 March 2022
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax		5,350.04
Adjustment for:		
Depreciation and amortization expense		587.52
Bad debts written off		130.23
Provision for expected credit loss		83.45
Finance cost		904.64
Interest income on bank deposits		(28.74)
Rent income		(7.80)
Loss on sale of fixed assets		10.63
Dividend income		(0.30)
Operating profit before working capital changes		7,029.66
Adjustments for changes in:		
Increase in inventories		(1,770.04)
Increase in trade receivables		(4,521.84)
Increase in other financial assets		(649.46)
Increase in other assets		(621.08)
Increase in other financial liabilities		89.26
Increase in provisions		44.89
Increase in trade payable		2,533.09
Increase in other current liabilities		389.93
Cash generated from operations		2,524.41
Income taxes paid (net of refund)		(52.69)
Net cash flow generated from operating activities		2,471.72
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment		(4,134.48)
Movement in fixed deposits		(343.35)
Dividend received		0.30
Interest received		28.74
Rent received		7.80
Net cash flow used in investing activities		(4,440.99)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from short term borrowings (net)		1,751.37
Proceeds from long term borrowings (net)		1,140.79
Proceeds from issue of share capital		-
Dividend paid		(103.53)
Interest paid		(795.87)
Net cash flow used in financing activities		1,992.76
Net Increase in cash and cash equivalents		23.49
Cash and cash equivalents at the beginning of the year		11.11
Cash and cash equivalents at the end of the year		34.60
Notes:		
Cash and cash equivalents include:		
Cash on hand		34.02
Balances with banks on current accounts		0.58
		34.60



CIN No:- L24230PB2006PLC030341
 GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	Quarter Ended		Year Ended
		31 March	31 December	31 March
		(Audited)	(Unaudited)	(Audited)
		2022	2021	2022
1	Segment revenue			
	a) Pharmaceuticals	9,586.99	4,711.91	34,866.94
	b) Printing and packagings	713.09	507.66	2,189.68
	Total	10,300.08	5,219.57	37,056.62
	Less: Inter segment revenue	762.31	258.54	1,626.45
	Revenue from operations	9,537.77	4,961.03	35,430.17
2	Segment results (profit before tax and finance cost from each segment)			
	a) Pharmaceuticals	1,030.04	349.30	6,084.22
	b) Printing and packagings	39.79	45.12	156.35
	Total	1,069.83	394.42	6,240.57
	Less: Finance costs	391.77	200.24	890.52
	Profit before tax	678.06	194.18	5,350.05

S.No.	Particulars	As at 31 March 2022 (Audited)
3	Segment Assets	
	a) Pharmaceuticals	26,511.12
	b) Printing and packagings	2,591.92
	Total Segment assets	29,103.04
4	Segment liabilities	
	a) Pharmaceuticals	18,200.11
	b) Printing and packagings	2,526.01
	Total Segment liabilities	20,726.13





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com



Ref. No.

Dated 30/05/2022

Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of ANG Lifesciences India Limited

Opinion

1. We have audited the accompanying consolidated annual financial results ("the Statement") of ANG Lifesciences India Limited ("the Holding Company") and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the year ended 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ("Listing Regulations"), including relevant circulars issued by the SEBI from time to time.
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) includes the annual financial results of the entity listed in Annexure 1
 - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (iii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group for the quarter and year ended 31 March 2022.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 30/05/2022

Responsibilities of Management and Those Charged with Governance for the Statement

- This Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible of ensuring accuracy of records including financial information considered necessary for preparation of the statement. Further, in terms of the provisions of the Act, the respective Board of Directors/ management of the companies included in the Group, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
- In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors/ management either intends to liquidate the Group or to cease operations or has no realistic alternative but to do so.
- The respective Board of Directors of the Company included in the Group, are responsible for overseeing the financial reporting process of the Company included in the Group.

Auditor's Responsibilities for the Audit of the Statement

- Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 20/05/2022

8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 30/05/2022

10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

11. The Statement includes the financial results for the quarter ended 31 March 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Raman Wadhwa & Co.
Chartered Accountants
Firm Registration No. 012037M


Ishant Sharma
Partner

Membership No. 527055
UDIN: 22527055AJYCA11474

Place: Amritsar
Date: 30 May 2022

Annexure I

Name of the entity included in the Statement

1. Mansa Print and Publisher Limited (w.e.f. 01 April 2021)

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

(₹ in lacs)		
Particulars	As at 31 March 2022 Audited	As at 31 March 2021 Audited
A. Assets		
1. Non-current assets		
(a) Property, plant and equipment	8,232.44	2,189.36
(b) Capital work-in-progress	-	40.07
(c) Financial assets		
(i) Investments	352.00	2.00
(ii) Other financial assets	98.24	385.51
(d) Deferred tax asset (net)	-	41.24
(e) Other non-current assets	29.02	377.24
Total non-current assets	8,711.70	3,035.42
2. Current assets		
(a) Inventories	2,916.59	1,925.87
(b) Financial assets		
(i) Trade receivables	9,898.81	5,878.37
(ii) Cash and cash equivalents	28.51	11.11
(iii) Other bank balances	630.37	-
iv) Other financial assets	1,147.76	496.01
(c) Other current assets	3,534.51	2,877.61
Total current assets	18,156.55	11,188.97
Total assets	26,868.25	14,224.39
B. Equity and liabilities		
Equity		
(a) Equity share capital	1,036.66	518.33
(b) Other equity	7,311.45	3,617.30
Total equity	8,348.11	4,135.63
Liabilities		
1. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	1,200.56	592.99
(ii) Trade payables	174.73	155.07
(iii) Other financial liabilities	1,547.80	28.57
(b) Deferred tax liabilities (net)	63.29	-
(c) Provisions	142.11	126.51
Total non-current liabilities	3,128.49	903.14
2. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	4,898.80	3,647.20
(ii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	6,003.04	885.54
- Total outstanding dues of creditors other than micro enterprises and small enterprises	623.84	3,638.25
(iii) Other financial liabilities	1,311.90	192.28
(b) Other current liabilities	645.35	320.52
(c) Provisions	17.59	24.44
(d) Current tax liabilities (net)	1,891.13	477.39
Total current liabilities	15,391.65	9,185.62
Total equity and liabilities	26,868.25	14,224.39



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone audited results for the quarter and year ended 31 March 2022

(₹ in lakhs except per share data)

Particulars	Quarter ended 31 March 2022	Quarter ended 31 December 2021	Quarter ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021
	(refer note 4)		(refer note 4)		
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I Revenue from operations	9,586.99	4,711.91	3,593.38	34,866.94	15,427.54
II Other income	62.33	13.46	57.78	95.15	74.62
III Total revenue (I+II)	9,649.32	4,725.37	3,651.16	34,962.09	15,502.16
IV Expenses					
Cost of materials consumed	6,956.66	4,305.66	2,538.26	23,448.55	10,825.93
Changes in inventories of finished goods and work-in-progress	(9.05)	(1,095.90)	(225.38)	(447.47)	(429.88)
Employee benefits expense	501.71	477.31	367.08	1,832.47	1,434.60
Finance costs	350.64	168.59	105.64	785.00	357.69
Depreciation and amortisation expenses	237.04	134.63	131.79	512.03	223.57
Other expenses	925.78	554.37	523.19	3,525.15	2,104.18
Total expenses (IV)	8,962.68	4,544.66	3,440.48	29,655.73	14,516.09
V Profit before exceptional items and tax (III-IV)	686.54	180.71	210.68	5,306.36	986.07
VI Exceptional items	-	-	-	-	-
VII Profit before tax (V-VI)	686.54	180.71	210.68	5,306.36	986.07
Tax expense					
(1) Current tax	221.50	65.00	98.00	1,346.50	318.00
(2) Deferred tax	(63.15)	(6.17)	(46.89)	(11.44)	(56.90)
VIII Total tax expense (1+2)	158.35	58.83	51.11	1,335.07	261.10
IX Profit for the period (VII-VIII)	528.19	121.88	159.57	3,971.30	724.97
X Other comprehensive income:					
Items that will not be reclassified to profit or (loss)	14.23	8.57	(23.41)	27.98	(93.66)
Income tax relating to items that will not be reclassified to profit or loss	(4.88)	(2.16)	5.89	(7.04)	23.57
XI Total comprehensive income (IX+X)	537.54	128.29	142.05	3,992.24	654.88
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,036.66	1,036.66	518.33	1,036.66	518.33
XIII Other equity				7,311.45	3,617.30
XIV Earnings per equity share (of ₹ 10/- each)					
a) Basic	5.19	1.24	2.74	38.51	12.63
b) Diluted	5.19	1.24	2.74	38.51	12.63

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Standalone Cash Flow Statement		(₹ in lacs)	
	Year ended 31 March 2022	Year ended 31 March 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit before tax	5,306.36	986.07	
Adjustment for:			
Depreciation and amortization expense	512.03	223.57	
Bad debts written off	130.23	35.10	
Provision for expected credit loss	83.45	-	
Reversal of expected credit loss	-	(8.68)	
Finance cost	785.00	357.69	
Interest income on bank deposits	(27.43)	(19.96)	
Dividend income	(0.30)	(0.30)	
Operating profit before working capital changes	6,789.34	1,573.49	
Adjustments for changes in:			
Increase in inventories	(990.73)	(925.44)	
Increase in trade receivables	(4,234.13)	(1,380.36)	
Increase in other financial assets	(651.75)	(281.72)	
Increase in other current assets	(658.69)	(1,802.67)	
Increase in other financial liabilities	58.64	71.01	
Increase in provisions	36.74	23.74	
Increase in trade payable	2,122.77	1,562.14	
Increase in other current liabilities	324.83	104.60	
Cash generated from operations	2,797.02	(1,055.21)	
Income taxes paid	(58.25)	(62.99)	
Net cash flow generated from operating activities	2,738.77	(1,118.20)	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(3,934.97)	(406.70)	
Investment in subsidiary	-	(350.00)	
Movement in fixed deposits	(343.12)	(42.46)	
Dividend received	0.30	0.30	
Interest received	27.43	19.96	
Net cash flow used in investing activities	(4,250.36)	(778.90)	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from short term borrowings (net)	1,251.61	2,005.00	
Proceeds from long term borrowings (net)	1,040.41	233.57	
Proceeds from issue of share capital	-	-	
Dividend paid	(103.53)	-	
Interest paid	(659.50)	(357.69)	
Net cash flow used in financing activities	1,528.99	1,880.88	
Net Increase in cash and cash equivalents	17.40	(16.22)	
Cash and cash equivalents at the beginning of the year	11.11	27.33	
Cash and cash equivalents at the end of the year	28.51	11.11	
Notes:			
Cash and cash equivalents include:			
Cash on hand	28.19	11.05	
Balances with banks on current accounts	0.32	0.06	
	28.51	11.11	



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The standalone and consolidated financial results for the quarter and year ended 31 March 2022 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 30 May 2022. The statutory auditors of the Company have expressed an unmodified opinion on these results.
3. The above results of ANG Life Sciences India Limited ('the Company' or 'the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 05 July, 2016 and other accounting principles generally accepted in India. Consequently, financial results for the quarter and year ended 31 March 2021 have been aligned to comply with Ind AS requirements to make them comparable with current periods.
4. Figures for the standalone and consolidated financial results for the quarter ended 31 March 2022 and 31 March 2021 are the balancing audited figures of the full financial year and the published year to date figures upto the third quarter of the year ended 31 March 2022 and 31 March 2021 respectively which were subjected to limited review by the statutory auditors of the Company.
5. The Board of Directors of the Company have approved the issue of 5,183,315 bonus equity shares on the record date i.e. 23 September 2021 in the proportion of 1 (One) equity share of Rs. 10/- each for every 1 (One) Equity Shares of Rs. 10/- each held by the shareholders of the Company as on the record date.
6. During the current year ended 31 March 2022, the holding Company has paid dividend of Rs. 1 per share.
7. The Holding Company has acquired Mansa Prints and Publishers Limited as per order of NCLT dated 18 March 2020 under Insolvency and Bankruptcy Code 2016, the proceedings of which was started on 28 February 2019. The order of Hon'ble National Company Law Tribunal was pronounced on 18 March 2020 wherein the Resolution Plan of ANG Life Sciences India Limited was approved. The payment of Rs. 1,350 lakhs was made by the Company in the form of 3,500,000 fully paid up equity shares of Rs. 350 lakhs and Rs. 1,000 lakhs as unsecured loans (by Company and its related parties).
8. Mansa Print and Publishers become 100% subsidiary of the Company w.e.f. 01 April 2021. Accordingly the consolidated results have been prepared and published for the the quarter ended 31 March 2022, 31 December 2021 and for the year ended 31 March 2022.
9. The Company has migrated from BSE SME platform to main board of BSE w.e.f. 08 November 2021.
10. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
11. Previous period figures have been re-grouped / reclassified wherever necessary to conform to current period's classification in order to comply with the requirements of the amended Schedule III of the Companies Act, 2013 effective from 01 April 2021.
12. The Board of Directors of the Company in its meeting held on 30 May 2022, have approved the issue of bonus equity shares in the proportion of 1 (One) equity share of Rs. 10/- each for every 4 (four) equity shares of Rs. 10/- each held by the shareholders of the Company as on the record date.

For and on behalf of the Board of Directors of
ANG Life Sciences India Limited



Place: Amritsar
Date: 30 May 2022





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com



Ref. No.

Dated. 20/05/2022

Independent Auditor's Report on Standalone Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ANG Lifesciences India Limited

Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of ANG Lifesciences India Limited ('the Company') for the year ended 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the quarter and year ended 31 March 2022.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com



Ref. No.

Dated. 30/05/2022

Responsibilities of Management and Those Charged with Governance for the Statement

- This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors.

The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

- In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
- The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

- Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com



Ref. No.

Dated. 30/05/2022

8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 30/05/2022

10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2022, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Raman Wadhwa & Co.
Chartered Accountants
Firm Registration No.: 012037M

Ishant Sharma
Partner

Membership No. 527055

UDIN: 22527055AJYGA11474

Place: Amritsar

Date: 30 May 2022

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

To

Department of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Mumbai- 400001

Ref: BSE Security Code-540694

Sub: **Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

In accordance with Reg. 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended by SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, it is hereby confirm and declare that the Statutory Auditors of the Company i.e. Raman Wadhwa & Co., Chartered Accountants, have issued the Audit Report on Standalone and Consolidated Financial Results of the Company for the year ended 31st March 2022 with unmodified opinion.

Thanking You,

Yours Faithfully

For ANG Lifesciences India Limited


Rajesh Gupta
Managing Director
(DIN: 01423407)